EGFR and non-small cell lung carcinoma: Three compounds, 6b, 7j and 9a, presented excellent inhibitory activity against gefitinib-resistant NSCLC cell line H1975 harboring EGFRL858R/T790M, indicating their potential against EGFR mutant cancer.